Chardan Capital assumed coverage on shares of Teladoc Inc. (NYSE:TDOC) in a research note released on Wednesday morning. The firm issued a buy rating and a $24.00 price objective on the stock.

Several other brokerages have also recently issued reports on TDOC. Oppenheimer Holdings Inc. set a $23.00 price objective on Teladoc and gave the stock a buy rating in a report on Sunday, October 30th. Zacks Investment Research cut Teladoc from a hold rating to a sell rating in a report on Tuesday, September 20th. FBR & Co reaffirmed a buy rating on shares of Teladoc in a report on Sunday, August 28th. Piper Jaffray Cos. reaffirmed an overweight rating and set a $21.00 price objective (down from $22.00) on shares of Teladoc in a report on Friday, August 5th. Finally, Deutsche Bank AG cut their price target on Teladoc from $21.00 to $20.00 and set a buy rating for the company in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the stock. Teladoc has an average rating of Buy and an average price target of $22.91.

Analyst Recommendations for Teladoc (NYSE:TDOC)

Teladoc (NYSE:TDOC) traded up 1.75% during trading on Wednesday, hitting $17.40. The stock had a trading volume of 84,931 shares. Teladoc has a one year low of $9.08 and a one year high of $22.00. The firm’s market cap is $800.96 million. The stock’s 50-day moving average is $16.71 and its 200 day moving average is $15.59.

Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Thursday, October 27th. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.03. The business earned $32.40 million during the quarter, compared to analysts’ expectations of $32.29 million. Teladoc had a negative return on equity of 32.68% and a negative net margin of 69.15%. The company’s quarterly revenue was up 62.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.35) EPS. Equities analysts anticipate that Teladoc will post ($1.42) earnings per share for the current year.

In other Teladoc news, VP Mark Hirschhorn sold 5,000 shares of the business’s stock in a transaction dated Thursday, November 10th. The stock was sold at an average price of $17.50, for a total transaction of $87,500.00. Following the transaction, the vice president now owns 267,687 shares in the company, valued at $4,684,522.50. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 5.94% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital World Investors boosted its position in Teladoc by 186.7% in the third quarter. Capital World Investors now owns 3,295,269 shares of the company’s stock valued at $60,336,000 after buying an additional 2,146,021 shares during the period. Peregrine Capital Management LLC acquired a new position in Teladoc during the third quarter valued at approximately $13,106,000. Sectoral Asset Management Inc. boosted its position in Teladoc by 50.1% in the second quarter. Sectoral Asset Management Inc. now owns 1,464,221 shares of the company’s stock valued at $23,457,000 after buying an additional 488,688 shares during the period. EverPoint Asset Management LLC acquired a new position in Teladoc during the second quarter valued at approximately $5,207,000. Finally, Tamarack Advisers LP acquired a new position in Teladoc during the third quarter valued at approximately $5,818,000. Institutional investors own 39.60% of the company’s stock.

About Teladoc

Teladoc, Inc, together with its subsidiaries, is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company operates through health services segment. Its solution connects its Members, with its over 3,000 board-certified physicians and behavioral health professionals who treat a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

5 Day Chart for NYSE:TDOC

Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.